Fine Barry, Vunjak-Novakovic Gordana
Department of Medicine, Engineering Columbia University, New York NY 10032.
Department of Biomedical Engineering Columbia University, New York NY 10032.
Curr Opin Physiol. 2020 Apr;14:56-63. doi: 10.1016/j.cophys.2020.01.004. Epub 2020 Jan 9.
In this short review, we draw parallels and stress differences between heart regeneration in mice and human, from a bioengineering perspective. As the prevailing dogma that the adult heart is completely post-mitotic is starting to change, there are multiple opportunities for augmenting the limited but definitive turnover of cardiomyocytes, to the extent necessary developing clinically relevant modalities for enhancing heart repair. We discuss some of the most promising among these new directions: mobilization of paracrine signaling by therapeutic cells, cell-free therapy of the heart using extracellular vesicles, and direct reprograming of endogenous cells. These new directions share the cell-free, mechanistic approach to heart repair that could be translated into the clinic faster and safer than the traditional cell therapies.
在这篇简短的综述中,我们从生物工程学角度比较并强调了小鼠和人类心脏再生之间的异同。随着认为成年心脏完全处于有丝分裂后期的主流观点开始改变,有多种机会增加心肌细胞有限但确定的更新,从而在必要程度上开发出增强心脏修复的临床相关方法。我们讨论了这些新方向中一些最有前景的方向:治疗性细胞对旁分泌信号的动员、利用细胞外囊泡对心脏进行无细胞治疗,以及对内源性细胞的直接重编程。这些新方向都采用无细胞的、基于机制的心脏修复方法,与传统细胞疗法相比,这种方法能够更快、更安全地转化应用于临床。